Assobiotec - English version

21 September 2021

3rd edition of the HealthTech Innovation Days - 4 & 5 October in Paris

Several speakers will share their views during the scheduled round-tables

07 September 2021

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system.

18 July 2021

Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases

Axxam is proud to announce that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round

12 July 2021

EryDel Announces Top-line Results from Phase3 ATTeST Trial Demonstrating Significant Clinical Benefit of EryDex in Ataxia Telangiectasia

EryDel SpA announced topline results from its Phase 3 ATTeST clinical trial in patients with Ataxia Telangiectasia (AT), a devastating neurological disease for which there is no approved therapy

05 July 2021

HealthTech For Care and EIT Health publish the agenda of the 3rd edition of the HealthTech Innovation Days event next 4 & 5 October 2021

Federchimica Assobiotec is one of the partner of this 3rd edition of the HealthTech Innovation Days (HTID®), placed under the High Patronage of Emmanuel Macron, President of the French Republic. The European healthcare ecosystem will gather around tomorrow's health major challenges: Artificial Intelligence, health data regulation, impact of the Covid-19 crisis and antibiotic resistance or robotics. The HTID mobilises both international sponsors and European clusters.

02 July 2021

Evotec creates long-term growth opportunities by initiating “Campus Levi-Montalcini” in Verona

Evotec acquires the Verona site from Gsk and secures capacity for long-term growth. Employees vote for site to be named “Campus Levi-Montalcini” in honour of Italian Nobel laureate Rita Levi-Montalcini

Go to the

News

3rd edition of the HealthTech Innovation Days - 4 & 5 October in Paris

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases

EryDel Announces Top-line Results from Phase3 ATTeST Trial Demonstrating Significant Clinical Benefit of EryDex in Ataxia Telangiectasia

HealthTech For Care and EIT Health publish the agenda of the 3rd edition of the HealthTech Innovation Days event next 4 & 5 October 2021

Evotec creates long-term growth opportunities by initiating “Campus Levi-Montalcini” in Verona

Partner

Where to find us

Go to the

News

3rd edition of the HealthTech Innovation Days - 4 & 5 October in Paris

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases

EryDel Announces Top-line Results from Phase3 ATTeST Trial Demonstrating Significant Clinical Benefit of EryDex in Ataxia Telangiectasia

HealthTech For Care and EIT Health publish the agenda of the 3rd edition of the HealthTech Innovation Days event next 4 & 5 October 2021

Evotec creates long-term growth opportunities by initiating “Campus Levi-Montalcini” in Verona

Partner

Where to find us

Our site uses cookies